Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2016

Concise asymmetric syntheses of novel phenanthroquinolizidines


Cintia Anton-Torrecillas,^a María Isabel Loza,^b José Brea^band Jose C. Gonzalez-Gomez,*^a


^aDepartamento de Química Orgánica, Facultad de Ciencias and Instituto de Síntesis Orgánica (ISO), Universidad de Alicante, Apdo. 99, 03080 Alicante, Spain.


^bGrupo de Investigación Biofarma. USEF screeningplatform. Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS). Universidad de Santiago de Compostela. Avda de Barcelona s/n. Santiago de Compostela, Spain.


josecarlos.gonzalez@ua.es


Content	Page
¹ H NMR and ¹³ C NMR spectra of compounds 2 to 7	2
¹ H NMR, ¹³ C NMR and HSQC spectra of compound 8	15
HPLC traces of <i>rac-8</i> and <i>ent-8/8</i>	18
¹ H NMR, ¹³ C NMR, COSY and NOESY spectra of compound 9	19
¹ H NMR, ¹³ C NMR, COSY and DPFGSE-NOE of compound 10	23
HPLC traces of compounds 10/ ent-10	27
Cytotoxicity assays of compounds 8/ent-8, 9/ent-9 and 10/ent-10	28












































COSY (300 MHz, CDCl₃)





HPLC traces of compounds rac-8 andent-8/8


CHIRALPAK IB column 4.6 mm x 250 mL; isocratic elution with 75:25:0.3, n-hexane/i-PrOH/TEA, 1.0 mL·min $^{-1}$; UV detection at 254 nm.

















COSY (300 MHz, CDCl₃) OMe MeO_{_}6 $H_{16},\,H_{11}$ H_9 15 Me ₁₄ MeO 10 ÓМе H_{15} 3.0 3.5 -4.0 4.5 4.0 3.5 f2 (ppm) 3.0 4.5 f1 (ppm) 3.0

7

8

11

10

6 5 f2 (ppm)


- 10

- 11

2.5 2.0 f2 (ppm) 1.5


3.0

DPFGSE-NOE when H₉ is irradiated (300 MHz, CDCl₃)



HPLC traces of compounds 10/ ent-10

CHIRALPAK IB column 4.6 mm x 250 mL; isocratic elution with 75:25:0.3, *n*-hexane/*i*-PrOH/TEA1.0 mL·min⁻¹; UV detection at 254 nm.



Cytotoxic Studies

All the cell lines employed were purchased to the American Tissue Culture Collection (ATCC) and grown following the instructions and media from the provider.

Cells were seeded in 96-well culture microplates and kept at 37°C in a 5% CO₂ atmosphere for 24 h. Solutions of test compounds in MeOHwere then added to each microplate, keeping 1% of MeOH, and incubated for different times depending on the cell line studied. After the incubation time cell viability was measured by using the tetrazolium dye assay (MTT method). Experiments were repeated three times.

Data was expressed as a percentage of inhibition in basis of the cell viability observed in vehicle-treated well following the formula:

%inhibition=100-((AO*100)/AT); where AO is the absorbance observed in the test well and AT is the absorbance observed in the vehicle-treated wells (with 1% of MeOH to consider the effect of the solvent). Concentration-% inhibitionwere fitted by using GraphPad Prism (v2.1) following the equation:

$$y = \frac{E_{\text{max}}}{1 + \frac{IC_{50}}{x}}^{n}$$


where Emax is the inhibition observed at the maximum concentration examined for each compound (100 μ M), IC₅₀ is the concentration that inhibits cell viability in a 50% and n is the Hill slope.

The seeding numbers and incubation times for each cell lines, as well as the concentration-response curves obtained for the compounds examined (including CDDP as a control experiment) were the following:

MCF-7

Seeding number: 10000


Incubation time with test compound:96 h





NCI-H460


Seeding number: 15000

Incubation time with test compound:48 h










HL-60

Seeding number: 10000

Incubation time with test compound: 24 h



NCI/ADR-RES

Seeding number: 15000

Incubation time with test compound: 48 h

